Question explored with the scientific record
What is the appropriate onset timing for ITP post influenza vaccine, assuming that the ITP was triggered by the influenza vaccine?
The short version: the evidence points to a tight 6-7 day onset window for vaccine-triggered ITP, but it comes from a single case report, not a population study.
The only direct evidence matching your question is a 2016 case report in Pediatrics [20]. A 4.5-year-old boy had three separate episodes of immune thrombocytopenia, each landing 6 to 7 days after his annual flu shot. The pattern was clean: symptoms appeared within a week of vaccination, he recovered fully between episodes, and when he skipped the shot one fall, no ITP occurred. The authors used the WHO-UMC causality system and rated the association "certain" [20]. A separate case report from 2013 describes Evans' syndrome (autoimmune destruction of both red cells and platelets) after influenza vaccine, but it does not specify the onset timing [21].
That is the entire evidence base. One child, three recurrences, a consistent window. No large observational study has tracked onset timing in a cohort of vaccine-associated ITP cases. No manufacturer-funded trial has reported this endpoint. The literature on influenza vaccine immunology in the retrieved evidence [1-19] is about antibody responses, T cell activation, and adjuvant effects in mice, elderly patients, and transplant recipients. None of it addresses ITP timing. The gap matters: a single case report establishes a plausible mechanism and a tight temporal signature, but it cannot tell you the incidence rate or whether the window varies by age, vaccine brand, or prior history.
| Evidence | Onset window | Population | Strength |
|---|---|---|---|
| Case report [20] | 6-7 days post-vaccination | Single child, 3 recurrences | High for timing, low for generalizability |
| Evans' syndrome case [21] | Not specified | Single adult | Does not answer the question |
My call: the appropriate onset timing for influenza vaccine-triggered ITP is 6 to 7 days post-injection, based on the only direct evidence available. Confidence: moderate for the timing claim itself, low for how well it generalizes beyond the reported case.
Sources examined 21
-
Cell-Cultured Influenza Vaccine Enhances IFN-γ+ T Cell and Memory T Cell Responses Following A/Victoria/2570/2019 IVR-215 (A/H1N1) Infection
This study compares the immune responses elicited by cell-cultured and egg-based influenza vaccines in BALB/c mice, demonstrating that the cell-cultured vaccine significantly enhances T cell responses and offers potential advantages for long-term immunity.
DOI: 10.3390/vaccines12121392 -
Effect of Lymphocyte miRNA Expression on Influenza Vaccine-Induced Immunity
This study investigates the role of lymphocyte miRNA expression in predicting immune responses to influenza vaccination, identifying specific miRNAs that correlate with antibody responses and may serve as biomarkers for vaccine efficacy.
DOI: 10.1101/2024.11.02.24316654 -
Immune response to influenza vaccination of elderly people. A randomized double-blind placebo-controlled trial
This study investigates the immune response to influenza vaccination in elderly individuals through a randomized double-blind placebo-controlled trial, finding that vaccination elicits a reasonable to good immune response in this population.
DOI: 10.1016/0264-410x(94)90241-0 -
Mechanism of enhancement of the immune responses to influenza vaccine with cholera toxin B subunit and a trace amount of holotoxin
This study investigates the mechanism by which cholera toxin B subunit and a trace amount of cholera toxin enhance immune responses to influenza vaccine in mice, demonstrating a synergistic effect on delayed-type hypersensitivity and macrophage activation.
DOI: 10.1016/0264-410x(95)98253-7 -
Old Rhesus Macaques Treated with Interleukin-7 Show Increased TREC Levels And Respond Well to Influenza Vaccination
This study demonstrates that treatment with recombinant simian interleukin-7 (IL-7) in aged rhesus macaques enhances T cell levels and improves immune responses to influenza vaccination without significant adverse effects.
DOI: 10.1089/rej.2006.9098 -
Suppression of the humoral immune response by mycophenolate mofetil
This study investigates the suppression of the humoral immune response to influenza vaccination in renal transplant recipients treated with mycophenolate mofetil (MMF), revealing significant reductions in antibody production compared to those treated with conventional immunosupp…
DOI: 10.1093/ndt/13.1.160 -
A target-based model for increasing influenza immunizations in private practice
This study evaluates the effectiveness of a target-based graphic tracking system in increasing influenza immunization rates among elderly patients in private practices, demonstrating a significant improvement in vaccination rates compared to a control group.
DOI: 10.1007/bf02598961 -
Lack of Association of Guillain-Barre Syndrome With Vaccinations
This study found no evidence of an increased risk of Guillain-Barré syndrome following vaccinations, including influenza vaccines, based on a large retrospective analysis of cases from Kaiser Permanente Northern California.
DOI: 10.1093/cid/cit222 -
Influenza vaccine: Delayed vaccination schedules and missed opportunities in children under 2 years old
This study investigates the high rates of delayed vaccination schedules and missed opportunities for influenza vaccination among children under 2 years old in Argentina, revealing significant associations with parental perceptions and information access.
DOI: 10.1016/j.vaccine.2015.06.065 -
Adjuvant activity of interferon alpha: mechanism(s) of action
This study investigates the adjuvant activity of interferon alpha (IFN␣) in enhancing the humoral immune response to influenza vaccination, revealing that the route of IFN administration significantly affects antibody production and the activation of immune cells.
DOI: 10.1016/j.vaccine.2005.01.117 -
Rapid loss of vaccine-acquired hepatitis B surface antibody after three doses of hepatitis B vaccination in HIV-infected persons
A retrospective chart review of HIV-infected adults vaccinated with three doses of hepatitis B vaccine shows rapid loss of vaccine-induced hepatitis B surface antibody (HBsAb), with seropositivity falling notably by 180–360 days and implications for follow-up serology testing at…
DOI: 10.1177/0956462413495820 -
Immunity in heifers 12 months after vaccination with a multivalent vaccine containing a United States Leptospira borgpetersenii serovar Hardjo isolate
This study evaluates the immunity induced by a multivalent vaccine containing a US Leptospira borgpetersenii serovar Hardjo isolate in heifers, demonstrating that vaccination at an early age prevents colonization and significantly reduces urine shedding 12 months post-vaccinatio…
DOI: 10.2460/javma.242.11.1573 -
Immune response after vaccination of HIV infected individuals receiving HAART with overlapping gag peptides pulsed on autologous cells
This study evaluates the safety and immunogenicity of a novel vaccine approach, Opal-HIV-Gag(c), in HIV-infected individuals on HAART, revealing limited CD8+ T cell responses and transient lymphopenia post-vaccination.
DOI: 10.1186/1742-4690-9-S2-P115 -
Immunization coverage among asplenic patients and strategies to increase vaccination compliance: a systematic review and meta-analysis
This study systematically reviews and meta-analyzes vaccination coverage among asplenic/splenectomized patients and evaluates strategies to improve vaccine adherence, finding generally suboptimal coverage across vaccines and showing that hospital-based protocols and enhanced hea…
DOI: 10.1080/14760584.2021.1886085 -
Response of Patients with Hodgkin's Disease to Pneumococcal Vaccine
In postsplenectomized patients treated for Hodgkin's disease, pneumococcal vaccination induced significantly lower serotype-specific antibody responses than normal controls, with responses improving over time after therapy and some patients failing to mount protective levels or …
DOI: 10.7326/0003-4819-90-6-887 -
The immune response to rabies virus infection and vaccination
This 2010 review synthesizes current understanding of the immune response to rabies virus infection and vaccination, highlighting neutralizing antibody as the key correlate of protection, the limited CNS antibody access due to CNS immunoprivilege, potential viral immunosuppressi…
DOI: 10.1016/j.vaccine.2010.03.039 -
Evaluation of a rapid passive hemagglutination assay for anti‐rubella antibody: Comparison to hemagglutination inhibition and a vaccine challenge study
This study evaluates a rapid passive hemagglutination assay (Rubaquick) for detecting anti-rubella antibodies in serum, demonstrating its high specificity and sensitivity compared to traditional hemagglutination inhibition assays and its effectiveness in assessing immune respons…
DOI: 10.1002/jmv.1890170304 -
Long-lasting humoral immune response induced in HIV-1-infected patients by a synthetic peptide (AT20) derived from the HIV-1 matrix protein p17 functional epitope
This study demonstrates that the synthetic peptide AT20, derived from the HIV-1 matrix protein p17, induces a long-lasting humoral immune response in HIV-1-infected patients undergoing HAART, maintaining high titers of neutralizing antibodies for over two years post-vaccination.
DOI: 10.1179/1528433614Z.0000000018 -
Measles antibody: comparison of long-term vaccination titres, early vaccination titres and naturally acquired immunity to and booster effects on the measles virus
This study compares long-term and early post-vaccination measles antibody titres, naturally acquired immunity, and the booster effects of revaccination in children, revealing significant differences in antibody levels and responses to vaccination.
DOI: 10.1016/0264-410x(94)90049-3 -
Recurrent Immune Thrombocytopenia After Influenza Vaccination: A Case Report
A case report describing a child who developed 3 episodes of immune thrombocytopenia (ITP), each occurring within 6-7 days after receiving the trivalent inactivated influenza vaccine, with full recovery between episodes and no recurrences after discontinuing seasonal influenza v…
DOI: 10.1542/peds.2016-0124 -
A Case of Evans' Syndrome Following Influenza Vaccine
This case report describes a 50-year-old man who developed Evans' syndrome following influenza vaccination, highlighting the potential hematological effects of the vaccine despite its widespread use.
DOI: 10.1016/j.jemermed.2012.01.060